Browse Articles

Investigating the Role of the Novel ESCRT-III Recruitment Factor CCDC11 in HIV Budding: A Potential Target for Antiviral Therapy

Takemaru et al. | Feb 24, 2020

Investigating the Role of the Novel ESCRT-III Recruitment Factor CCDC11 in HIV Budding: A Potential Target for Antiviral Therapy

Acquired immunodeficiency syndrome (AIDS) is a life-threatening condition caused by the human immunodeficiency virus (HIV). In this work, Takemaru et al explored the role of Coiled-Coil Domain-Containing 11 (CCDC11) in HIV-1 budding. Their results suggest that CCDC11 is critical for efficient HIV-1 budding, potentially indicating CCDC11 a viable target for antiviral therapeutics without major side effects.

Read More...

Phages Can Be More Effective and Specific Than Antibiotics in Combating Bacteria

Wu et al. | Feb 17, 2019

Phages Can Be More Effective and Specific Than Antibiotics in Combating Bacteria

Phage therapy has been suggested as an alternative to antibiotics because bacteria resistant to antibiotics may still be susceptible to phages. However, phages may have limited effectiveness in combating bacteria since bacteria possess several antiviral defense mechanisms and can quickly develop resistance to phages. In this study, Wu and Pinta compare the effectiveness and specificity of antibiotics and phages in combating bacteria. They found that T4 phages are more specific and effective in fighting or inhibiting both antibiotic-resistant and sensitive bacteria than antibiotics, suggesting that phage therapy can be developed as an efficient tool to combat antibiotic-resistant bacteria.

Read More...

Homology modeling of clinically-relevant rilpivirine-resistant HIV-RT variants identifies novel rilpivirine analogs with retained binding affinity against NNRTI-resistant HIV mutations

Luk et al. | Jan 24, 2022

Homology modeling of clinically-relevant rilpivirine-resistant HIV-RT variants identifies novel rilpivirine analogs with retained binding affinity against NNRTI-resistant HIV mutations

Human immunodeficiency virus (HIV), which affects tens of millions of individuals worldwide, can lead to acquired immunodeficiency syndrome (AIDS). While there is currently no cure for HIV, the development of small molecule antiretroviral agents has greatly improved the prognosis of infected individuals, especially in developed countries. Here, the authors employ homology modeling and molecular docking towards the identification of novel rilpivirine analogs that retain high binding affinity to clinically relevant rilpivirine-resistant mutations of the HIV reverse transcriptase enzyme.

Read More...